Getting your player ready...
Geron, the company that launched the first U.S.-authorized therapy using human embryonic stem cells, is ending the program to focus on its cancer drugs.
Geron will eliminate 66 full-time jobs, or 38 percent of its workforce, and take a cash charge of $5 million in the fourth quarter and $3 million in the first half of 2012, the Menlo Park, Calif.-based company said Monday.
Geron began the first trial evaluating its embryonic-stem-cell therapy in spinal-cord- injury patients in April. In October, it reported that none of the four patients in the trial had experienced negative reactions to the therapy.
Denver Post staff and wire reports
